Earnings Ahead

AGIO - Agios Pharmaceuticals

28.13 0.66 2.4

Agios Pharmaceuticals

Agios Pharmaceuticals

About

Profile


Headquarters

Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

AGIO



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Agios Pharmaceuticals GAAP EPS of -$6.33 misses by $0.07, revenue of $26.82M misses by $0.9M
  • Agios Pharmaceuticals Q4 2023 Earnings Preview
  • AIM stock dips amid mixed results for post-COVID fatigue therapy
  • CRISPR, bluebird stocks slide as Agios rallies on thalassemia study
  • Agios stock rallies after mitapivat meets key goal in thalassemia trial
  • Agios Pharmaceuticals GAAP EPS of -$1.64 beats by $0.06, revenue of $7.4M misses by $0.13M
  • Agios Pharmaceuticals Q3 2023 Earnings Preview
  • Agios Pharmaceuticals GAAP EPS of -$1.51 beats by $0.05, revenue of $6.7M beats by $0.24M
  • Agios Pharmaceuticals Q2 Earnings Preview
  • Agios Pharmaceuticals GAAP EPS of -$1.47 beats by $0.23, revenue of $5.6M beats by $0.37M
  • Agios Pharmaceuticals Q1 2023 Earnings Preview
  • Agios Pharmaceuticals GAAP EPS of -$4.23 beats by $2.06, revenue of $14.24M beats by $0.35M
  • Agios rare blood disorder drug Pyrukynd sustains benefits in patients in long term data
  • Agios Pharmaceuticals upgraded to neutral at Goldman Sachs on Pyrukynd outlook
  • Agios granted EU approval for Pyrukynd in pyruvate kinase deficiency
  • Agios Pharmaceuticals GAAP EPS of -$1.49 beats by $0.27, revenue of $3.52M misses by $1.72M
  • Agios sells its rights to royalties on U.S. sales of cancer drug Tibsovo for $131.8M
  • Agios appoints Cecilia Jones as finance chief
  • Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
  • Agios CFO Jonathan Biller to quit

Earnings History

Date EPS / Forecast Revenue / Forecast
February 24, 2022 -1.81 / -1.66 - / 410K
November 3, 2021 -1.48 / -1.57 - / 2.55M
July 29, 2021 -1.41 / -1.33 - / -
April 29, 2021 26.95 / -1.29 - / -
February 25, 2021 -1.41 / -1.31 44.05M / 39.86M Beat!
November 5, 2020 -1.43 / -1.36 34.71M / 38.12M
July 30, 2020 -1.31 / -1.36 37.35M / 37.14M Beat!
April 30, 2020 -0.59 / -1.67 87.1M / 31.12M Beat!
February 13, 2020 -1.6 / -1.7 35.44M / 33.72M Beat!
October 31, 2019 -1.81 / -1.8 26.02M / 33.13M
August 1, 2019 -1.87 / -1.7 26.22M / 27.01M
May 2, 2019 -1.59 / -1.75 30.23M / 22.69M Beat!
February 14, 2019 -1.58 / -1.67 30.01M / 18.83M Beat!
November 1, 2018 -1.63 / -1.62 15.2M / 19.12M
August 2, 2018 -1.19 / -1.57 40.41M / 9.95M Beat!
May 4, 2018 -1.63 / -1.63 8.76M / 10.84M
February 14, 2018 - / -1.66 - / 13.34M
November 1, 2017 -1.59 / -1.79 11.36M / 9.77M Beat!
August 8, 2017 -1.78 / -1.73 11.35M / 9.62M Beat!
May 4, 2017 -1.56 / -1.54 10.51M / - Beat!
February 16, 2017 -1.34 / -1.48 22.65M / 16.03M Beat!
November 3, 2016 -1.63 / -1.45 8.99M / 7.19M Beat!
Date Price Open High Low Vol Change ER
Oct 9, 2023 24.01 23.83
24.1
23.52
357K 0.04%
Oct 6, 2023 24 24.29
24.45
23.62
444K -2.16%
Oct 5, 2023 24.53 23.85
24.89
23.67
916K 2.29%
Oct 4, 2023 23.98 24.07
24.14
23.65
208K -0.17%
Oct 3, 2023 24.02 24.04
24.36
23.81
194K -0.83%
 
Oct 2, 2023 24.22 24.74
24.74
23.84
327K -2.14%
Sep 29, 2023 24.75 24.97
25.2
24.5
439K -0.08%
Sep 28, 2023 24.77 24.43
24.79
24.04
213K 0.98%
Sep 27, 2023 24.53 24.43
24.94
24.25
503K 0.70%
Sep 26, 2023 24.36 24.41
25.03
24.2
307K -0.2%
Sep 25, 2023 24.41 24.47
24.79
24.06
277K -0.49%
Sep 22, 2023 24.53 24.93
25.04
24.4
223K -1.49%
Sep 21, 2023 24.9 24.37
25.02
24.21
223K 1.38%
Sep 20, 2023 24.56 25.07
25.24
24.52
232K -2.03%
Sep 19, 2023 25.07 25.45
25.51
24.78
217K -1.53%
Sep 18, 2023 25.46 26.19
26.51
25.39
267K -2.41%
Sep 15, 2023 26.09 26.88
26.97
25.73
1.0M -2.94%
Sep 14, 2023 26.88 27.48
27.64
26.8
832K -1.36%
Sep 13, 2023 27.25 27.08
27.34
26.84
296K 0.52%
Sep 12, 2023 27.11 26.94
27.47
26.77
246K 0.89%
Sep 11, 2023 26.87 26.12
26.88
25.94
248K 2.91%
Sep 8, 2023 26.11 26.12
26.4
25.66
218K 0.27%
Sep 7, 2023 26.04 26.45
26.45
25.84
287K -1.96%
Sep 6, 2023 26.56 27.1
27.26
26.38
271K -1.48%
Sep 5, 2023 26.96 28.01
28.12
26.89
261K -4.3%
Sep 1, 2023 28.17 27.61
28.49
27.26
371K 2.70%
Aug 31, 2023 27.43 27.18
27.62
27.04
496K 0.59%
Aug 30, 2023 27.27 26.93
27.34
26.84
348K 0.96%
Aug 29, 2023 27.01 27.05
27.22
26.65
273K 0.22%
Aug 28, 2023 26.95 27.13
27.39
26.43
219K -0.07%
Aug 25, 2023 26.97 26.62
27.29
26.42
207K 1.43%
Aug 24, 2023 26.59 26.81
26.82
26.15
240K -1.19%
Aug 23, 2023 26.91 27.1
27.49
26.76
308K -0.48%
Aug 22, 2023 27.04 26.9
27.19
26.78
247K 0.48%
Aug 21, 2023 26.91 26.13
27.11
25.9
399K 2.55%
Aug 18, 2023 26.24 25.66
26.55
25.6
245K 1.04%
Aug 17, 2023 25.97 26.77
26.95
25.85
297K -2.73%
Aug 16, 2023 26.7 27.56
27.82
26.19
407K -3.78%
Aug 15, 2023 27.75 27.49
27.8
27.03
298K 0.80%
Aug 14, 2023 27.53 26.38
27.61
26.02
339K 3.26%
Aug 11, 2023 26.66 26.75
27.08
26.52
275K -0.49%
Aug 10, 2023 26.79 25.96
27.13
25.93
355K 2.76%
Aug 9, 2023 26.07 26.02
26.5
25.67
454K 0.27%
Aug 8, 2023 26 25.37
26.06
25.2
523K 1.76%
Aug 7, 2023 25.55 25.46
25.99
25.21
388K 0.35%
Aug 4, 2023 25.46 25.77
25.93
25.05
302K -1.85%
Aug 3, 2023 25.94 25.23
26.74
25.23
368K -0.15%
Aug 2, 2023 25.98 26.4
26.4
25.65
386K -3.02%
Aug 1, 2023 26.79 26.5
26.85
26.03
409K 1.02%
Jul 31, 2023 26.52 26.62
27.03
26.25
236K -0.23%
Jul 28, 2023 26.58 26.35
26.62
25.74
355K 3.83%
Jul 27, 2023 25.6 26.24
26.37
25.46
268K -1.77%
Jul 26, 2023 26.06 26.15
26.39
25.76
228K -0.72%
Jul 25, 2023 26.25 26.39
26.64
26.15
204K -0.3%
Jul 24, 2023 26.33 27.47
27.72
26.29
344K -4.32%
Jul 21, 2023 27.52 27.03
27.74
26.83
844K 2.61%
Jul 20, 2023 26.82 26.49
26.88
26.26
355K 1.32%
Jul 19, 2023 26.47 27.13
27.39
26.45
347K -1.74%
Jul 18, 2023 26.94 27.03
27.3
26.86
264K -0.81%
Jul 17, 2023 27.16 27.26
27.94
27.13
312K 0%